IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway
Figure 4
Inhibition of MEK/ERK pathway by inhibitors confers the inhibition effect of IGHG1. Cells transfected with or without IGHG1 siRNA fragments with added MEK/ERK inhibitors PD98059 and U0126 and MEK/ERK activator PAF(C-16). The cell lysates were subjected to western blot. The representative images were shown in (a), (e) in DU145 cells and (c), (g) in PC3 cells of activation of MEK and ERK and the statistical data were shown in (b), (f) in DU145 cells and (d), (h) in PC3 cells with the expression of c-Myc, Cyclin D1, and p21. The DU145 (i) and PC3 (j) cells with indicated administrations were subjected to MTS assay to evaluate the cell growth. The data of 0 h, 12 h, 24 h, and 48 h after transfection was shown as the growth rate. Data are expressed as the mean ± SD. denotes p < 0.05, compared with si-Ctrl group; # denotes p < 0.05, compared with si-IGHG1 group.